8-K: NKGen Biotech Amends Loan Agreement with East West Bank, Extends Maturity Date and Modifies Payment Terms

NKGen Biotech modifies its loan agreement with East West Bank, extending the maturity date to January 15, 2027, and adjusting the interest rate and payment schedule.

Summary

• NKGen Biotech, Inc. amended its loan agreement with East West Bank on April 21, 2025, with retroactive effect from April 14, 2025.
• The amendment extends the maturity date of the secured convertible promissory note to January 15, 2027.
• The interest rate on the outstanding principal increased to a fixed 10% per annum, payable monthly.
• NKGen Biotech deposited $250,000 into a restricted account for monthly interest payments.
• A principal-only amortization schedule was established, including payments of $1,000,000 due on June 1, 2025, $1,000,000 due on July 15, 2025, and $500,000 due on October 15, 2025, with subsequent quarterly payments of $500,000 thereafter.
• The interest rate will increase by 5 percentage points upon the Maturity Date or acceleration due to default, but will not exceed the maximum rate permitted by law.
• The original principal amount of the loan was $5,000,000, but the principal amount of the Note was $3,991,127.50 as of April 14, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the loan modification provides short-term relief, the increased interest rate and restricted account could pose challenges in the long run.

Positives

• Extending the maturity date to January 15, 2027 provides NKGen Biotech with more time to repay the loan.
• The loan agreement includes a provision to release the lien of the deed of trust securing the real property collateral upon payment in full of the indebtedness or pledge of cash collateral.

Negatives

• The interest rate on the loan increased to a fixed 10% per annum, increasing the cost of borrowing.
• The company is required to deposit $250,000 into a restricted account, limiting its access to those funds.
• The loan agreement includes a provision for a 5 percentage point increase in the interest rate upon maturity or default.

Risks

• Failure to meet the principal payment schedule could trigger a default under the loan agreement.
• An increase in the interest rate by 5 percentage points upon maturity or default could further strain the company's finances.
• Depletion of the reserve account could lead to a default if the Borrower does not promptly replenish the Reserve Account prior to its depletion.

Future Outlook

The amendment provides NKGen Biotech with an extended repayment timeline and revised payment terms, but also increases the interest rate and requires a restricted account for interest payments.

Management Comments

• Paul Y. Song, CEO/Secretary of NKGen Biotech, signed the Loan Agreement Amendment on behalf of the company.

Industry Context

Many biotech companies rely on debt financing to fund research and development. Modifying loan terms is a common practice to manage cash flow and extend operational runway.

Comparison to Industry Standards

• Interest rates for similar loans to biotech companies can vary widely depending on the company's stage of development, creditworthiness, and the overall market conditions.
• Securing loan modifications is a common strategy for companies facing short-term liquidity challenges, but it often comes at the cost of higher interest rates or stricter covenants.
• Comparable companies might include other small-cap biotech firms that have recently restructured their debt obligations to extend maturity dates and manage cash flow.

Stakeholder Impact

• Shareholders may view the loan modification as a positive step towards financial stability, but the increased interest rate could raise concerns about profitability.
• Employees may be reassured by the extended maturity date, but the company's financial performance will continue to be closely monitored.
• Creditors will benefit from the increased interest rate and the restricted account for interest payments.

Next Steps

• NKGen Biotech must adhere to the new amortization schedule and ensure timely interest payments.
• The company needs to monitor its cash flow to replenish the restricted account as needed.
• NKGen Biotech should explore long-term financing options to reduce its reliance on debt.

Key Dates

Keywords

Loan Agreement, NKGen Biotech, East West Bank, Maturity Date, Interest Rate, Promissory Note, Amendment, Debt Financing